Oral post-treatment supplementation with a combination of glutamine, citrulline, and antioxidant vitamins additively mitigates jejunal damage, oxidative stress, and inflammation in rats with intestinal ischemia and reperfusion
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0298334 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Yu-Wen Chiu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutritional Science, Fu Jen Catholic University, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Antioxidants, Reperfusion Injury. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Council of the Republic of China.
Abstract (Originalsprache)
Introduction
Intestinal ischemia and reperfusion (IIR) injury is closely associated with oxidative stress. Evidence shows that oral supplementation with glutamine and citrulline alleviates IIR-induced jejunal damage. We investigated the effects of a combination of glutamine, citrulline, and antioxidant vitamins on IIR-induced jejunal damage, oxidative stress, and inflammation.
Method
Male Wistar rats that underwent 60 min of superior mesenteric artery occlusion were orally administered glutamine plus citrulline (GC), vitamin C plus E (CE), or a combination of GC and CE 15 min before and 3, 9, and 21 h after reperfusion. Healthy rats without IIR were used as controls.
Results
After reperfusion for 24 h, rats with IIR showed lower levels of red blood cells, hemoglobin, serum glucose, and jejunal DNA and increased white blood cell counts compared to controls (1-way ANOVA with the least significant difference, P < 0.05). The IIR-induced decrease in serum albumin and increase in plasma interleukin-6 and jejunal thiobarbituric acid-reactive substances (TBARS) were significantly reversed by GC and/or CE. The results of the 2-way ANOVA indicated that GC was the main factor that increased jejunal villus height and muscularis DNA, and CE was the main factor that increased jejunal muscularis protein and decreased jejunal proinflammatory cytokine levels and myeloperoxidase activity. In addition, GC and CE are the main factors that decrease plasma proinflammatory cytokine levels and the jejunal apoptotic index.
Conclusion
Oral post-treatment supplementation with glutamine and citrulline, combined with vitamins C and E, may alleviate IIR-induced oxidative stress, inflammation, and jejunal damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nutritional Science, Fu Jen Catholic University, New Taipei City, Taiwan.
- Lee's Endocrinology Clinic, Pingtung City, Pingtung County, Taiwan.
- School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan.
- Department of Surgery, Division of Pediatric Surgery, China Medical University Children's Hospital, Taichung, Taiwan.
ORCID-Profile: Hui-Chen Lo
Förderung
- National Science Council of the Republic of China
Zitieren
APA
Chiu, Y. W., Lee, C. H., & Lo, H. C. (2024). Oral post-treatment supplementation with a combination of glutamine, citrulline, and antioxidant vitamins additively mitigates jejunal damage, oxidative stress, and inflammation in rats with intestinal ischemia and reperfusion. PLOS ONE. https://doi.org/10.1371/journal.pone.0298334
Vancouver
Chiu YW, Lee CH, Lo HC. Oral post-treatment supplementation with a combination of glutamine, citrulline, and antioxidant vitamins additively mitigates jejunal damage, oxidative stress, and inflammation in rats with intestinal ischemia and reperfusion. PLOS ONE. 2024. doi:10.1371/journal.pone.0298334
BibTeX
@article{Chiu2024,
author = {Chiu, Yu-Wen and Lee, Chien-Hsing and Lo, Hui-Chen},
title = {Oral post-treatment supplementation with a combination of glutamine, citrulline, and antioxidant vitamins additively mitigates jejunal damage, oxidative stress, and inflammation in rats with intestinal ischemia and reperfusion},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0298334}
}
EUVIMED